Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 77.93M P/E - EPS this Y 54.70% Ern Qtrly Grth -
Income -65.53M Forward P/E -1.15 EPS next Y 54.00% 50D Avg Chg 1.00%
Sales 2.36M PEG - EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book 0.92 EPS next 5Y - 52W High Chg -42.00%
Recommedations 2.00 Quick Ratio 1.94 Shares Outstanding 43.95M 52W Low Chg 46.00%
Insider Own 40.93% ROA -45.76% Shares Float 15.62M Beta -0.06
Inst Own 30.22% ROE -130.03% Shares Shorted/Prior 14.75K/111.28K Price 2.84
Gross Margin 100.00% Profit Margin - Avg. Volume 15,374 Target Price 5.50
Oper. Margin -622.57% Earnings Date Nov 9 Volume 831 Change 1.07%
About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics, Inc. News
11/07/24 Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
11/07/24 Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
10/30/24 Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
10/04/24 Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
10/02/24 Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/28/24 Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
08/08/24 Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
06/29/24 Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth?
06/13/24 Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
05/29/24 Gilead and Cartography enter deal to develop cancer therapies
05/14/24 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
04/16/24 Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
04/01/24 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
03/28/24 Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
03/28/24 Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
03/28/24 Gilead bets on Xilio cancer drug as biotech restructures
02/28/24 Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
01/31/24 Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
01/08/24 Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
12/07/23 Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
XLO Chatroom

User Image LabPsycho Posted - 11/29/24

$XLO I can not find my other post around the time of this one below many months ago, but I speculated back in April, something to the effect of 'by this time next year [April 2025], XLO could have $100M cash.' So far, not much has changed about my gut feeling back then, even in light of the expected pounding of biotechs (also predicted) that has happened since then. I just do not know if biotechs are coming off the bottom now or another couple weeks (or more) of misery.

User Image EZ904Duval Posted - 11/29/24

$XLO

User Image Tshanky_ Posted - 11/27/24

$XLO gonna be a banger.

User Image AnalRetort Posted - 11/26/24

$xlo Gilead pay that man his money https://x.com/Banana_Oncology/status/1852509388054859822?t=lt6eLmNn3Q1C6rAmWBGPWw&s=19

User Image AnalRetort Posted - 11/26/24

@Tshanky_ fyi the $75 million from Gilead is looking solid. https://x.com/Banana_Oncology/status/1852509388054859822?t=lt6eLmNn3Q1C6rAmWBGPWw&s=19 $xlo I'm back in.

User Image Tshanky_ Posted - 11/26/24

$XLO I see this over 2 in due time imo

User Image Tshanky_ Posted - 11/26/24

$XLO 👀

User Image Tshanky_ Posted - 11/25/24

$XLO

User Image LabPsycho Posted - 11/19/24

$XLO @ErnieWorthing84 Well, to me it means, unlike scores of other biotechs that are downsizing and laying off 40% of their workforce, XLO is hiring.

User Image ErnieWorthing84 Posted - 11/18/24

$XLO Doesn't necessarily mean anything, but they've opened seven (clinical/engineering/regulatory affairs) job listings in the past month or so

User Image ErnieWorthing84 Posted - 11/15/24

$XLO Quite the PA today...

User Image biohuntress Posted - 11/14/24

$XLO https://xiliotx.gcs-web.com/node/8316/html

User Image biohuntress Posted - 11/14/24

$XLO Bain capped at 9.99% ownership if I'm reading correctly....did they add or execise some warrants?

User Image Paper_Route_Frank Posted - 11/14/24

$XLO looking to add more soon

User Image biohuntress Posted - 11/11/24

$XLO any idea when they deliver the data package to Gilead and when does GILD hand over the $75M if they like the data?

User Image Carti_Crae Posted - 11/09/24

$XLO is dilution complete?

User Image EZ904Duval Posted - 11/08/24

$XLO money is coming keep calm

User Image OracleofOntario Posted - 11/08/24

$XLO 7 days it closed above $1 but it needed 10 consecutive days to fulfill the Nasdaq minimum bid price requirement and today it closed below $1. So I believe it has to start from the beginning and close 10 more consecutive days above $1.

User Image RallyRaider Posted - 11/07/24

$XLO mount

User Image kindadumb25 Posted - 11/07/24

$XLO come on you shortselling fucks, pop it back over a dollar for compliance its still much cheaper than what you sold at this am

User Image biohuntress Posted - 11/07/24

$XLO seems like the story is intact....the PH1 data is old news that was used to justify PH2 with Roche....the dilution knocked it down it seems

User Image EZ904Duval Posted - 11/07/24

$XLO $LYEL $WATT $ZNTL $BWEN this is my gang sent to get money. Next week won’t have the same story

User Image the_real_Joker Posted - 11/07/24

$XLO hmm still high cash burning but good results expecting? time 4 rebound here?

User Image ErnieWorthing84 Posted - 11/07/24

$XLO Kinda odd that they would have a call about this 1c data (given the paucity of calls that they hold more generally)

User Image KUMU Posted - 11/07/24

$XLO very nice short trade

User Image biohuntress Posted - 11/07/24

$XLO there was dilution...63M shares now..... need to see if GILD came in for more...XLO CEO said they have the option to pull down 17.5M cash + 8.5M equity from the GILD deal....also need to regain compliance

User Image ErnieWorthing84 Posted - 11/07/24

$XLO

User Image biohuntress Posted - 11/07/24

$XLO the expectation was for the PH2 mssCRC data which is due this Q4and still on schedule....https://xiliotx.gcs-web.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-clinical-trial-data-phase

User Image KUMU Posted - 11/07/24

$XLO big short here

User Image MountAnahuac Posted - 11/07/24

$XLO damn everyone is selling 😭

Analyst Ratings
Chardan Capital Buy May 30, 23
Chardan Capital Buy May 11, 23
Morgan Stanley Overweight Jan 27, 23
Chardan Capital Buy Dec 21, 22
Raymond James Outperform Nov 10, 22
Morgan Stanley Overweight Aug 10, 22
HC Wainwright & Co. Buy Jan 10, 22
Raymond James Outperform Nov 16, 21
Cowen & Co. Outperform Nov 16, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Atlas Venture Fund XI, L.P. 10% Owner 10% Owner Jan 11 Sell 0.85 4,235 3,600 734,813 01/16/24
Bain Capital Life Sciences Inv... 10% Owner 10% Owner Dec 08 Buy 9.82 42,469 417,046 2,805,413 12/10/21
Flynn James E - - Oct 26 Buy 16 775,000 12,400,000 1,143,972 10/28/21